While Europe’s biotech sector continues to face headwinds, med tech appears to be weathering the storm more effectively. Uncertainty in the U.S., heightened competition from China and a persistent ...
About a month after rolling out positive phase I/II data with its candidate for metastatic, castrate-resistant prostate ...
Over a span of five-and-a-half months this year, 3.5% of the more than 11,000 clinical trials funded by the U.S. NIH had ...
By transplanting a pig kidney into a brain-dead person, researchers have been able to conduct the first long-term study of the physiological processes occurring in both the transplant recipient and ...
Mitorx Therapeutics Ltd. has raised £5.5 million (US$7.2 million) in a pre-series A round to advance its lead ...
DNA damage response specialist Artios Ltd. has closed an oversubscribed $115 million series D after delivering positive phase ...
Coave Therapeutics SA has nominated a lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...
The Medicare Wasteful and Inappropriate Service Reduction (WISeR) proposal is designed to tamp down on waste, fraud and abuse ...
Researchers from Arcus Biosciences Inc. described the antitumor efficacy of AB-801, an AXL inhibitor in several cancer models ...
Fresh cash infusions are on the way for European biotech after two leading venture capital firms announced large new funds.
New hires and promotions in the med-tech industry, including: Micro Medical Solutions, Onco Nano, Seastar Medical, Tecan Group. Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web ...
Researchers from Tango Therapeutics Inc. presented preclinical efficacy data on TNG-260, an inhibitor of the co-repressor of repressor element-1 silencing transcription (CoREST) deacetylase complex, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback